Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer

Figures & data

Figure 1 Chemical structure of crizotinib (A) and ALK in complex with crizotinib (B).

Abbreviation: ALK, anaplastic lymphoma kinase.

Table 1 Characteristics of the clinical studies of crizotinib

Study	Trial	ID	Design	Number	PFS (months)	ORR (%)
Kwak et al^Citation9	Phase I	PROFILE 1001	Single arm	149	9.7	60.8
Camidge et al^Citation17
Crinò et al^Citation40	Phase II	PROFILE 1005	Single arm	259	8.5	53
Kim et al^Citation41
Shaw et al^Citation13	Phase III	PROFILE 1007	Second line Crizotinib vs pemetrexed or docetaxel	347	7.7	65
Solomon et al^Citation44	Phase III	PROFILE 1014	First line Crizotinib vs pemetrexed/cisplatin or carboplatin	343	10.9	74

Abbreviations: PFS, progression-free survival; ORR, objective response rate; ID, identification.

Table 2 The efficacy of crizotinib compared with standard chemotherapy in previously treated patients with NSCLC

Efficacy parameter	Crizotinib (N=173)	Pemetrexed or docetaxel (N=174)
PFS (months) (95% CI)	7.7 (6.0–8.8)	3.0 (2.6–4.3)
ORR (%) (95% CI)	65 (58–72)	20 (14–26)
Median duration of response (weeks) (range)	32.1 (2.1–72.4)	24.4 (3.0–43.6)
Median time to response (weeks) (range)	6.3 (4.4–48.4)	12.6 (5.0–37.1)

Abbreviations: NSCLC, non-small-cell lung cancer; PFS, progression-free survival; CI, confidence interval; ORR, objective response rate.

KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469

 PubMed Web of Science ®Google Scholar

CamidgeDRBangYJKwakELActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyLancet Oncol201213101011101922954507

 PubMed Web of Science ®Google Scholar

CrinòLKimDRielyGJInitial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE1005J Clin Oncol201129suppl7514

 Web of Science ®Google Scholar

KimDAhnMShiYUpdated results of a global phase II study with crizotinib in advanced ALK positive NSCLCAnn Oncol201223suppl 9402

 Google Scholar

ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med2013368252385239423724913

 PubMed Web of Science ®Google Scholar

SolomonBJMokTKimDWPROFILE 1014 InvestigatorsFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694

 PubMed Web of Science ®Google Scholar